Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to NeoGenomics, Inc. (NASDAQ: NEO) SEC filings, offering a regulatory view of the company’s activities as a public cancer diagnostics business. NeoGenomics is a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol NEO, as disclosed in its Form 8-K filings.
Investors can review current reports on Form 8-K, which NeoGenomics uses to furnish quarterly financial results, preliminary revenue updates, and information about board and executive changes. Recent 8-K filings have reported results for fiscal quarters, described financial metrics such as revenue and operating expenses, and documented director appointments and resignations.
Through this page, users can also monitor quarterly and annual reports (Forms 10-Q and 10-K when available) that typically include detailed discussions of the company’s oncology diagnostics operations, risk factors, and financial statements. These filings complement the company’s news releases describing clinical test volumes, next-generation sequencing contributions, and research and development spending.
For those tracking governance and corporate actions, the SEC filings detail matters such as board composition and compensation arrangements for directors, as reflected in 8-K disclosures about board changes. Filings related to financial results often reference non-GAAP measures like Adjusted EBITDA and Adjusted Gross Profit Margin, with reconciliations and definitions included in the attached press releases.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight notable changes from prior periods, and make it easier to locate items related to revenue trends, operating performance, and governance updates. Real-time updates from EDGAR help ensure that new NeoGenomics filings, including any future Forms 10-K, 10-Q, or Form 4 insider transaction reports, are quickly reflected and summarized for NEO investors and researchers.
Neogenomics, Inc. amendment filing reports that First Light Asset Management, LLC beneficially owns 13,631,016 shares (10.47%) and Mathew P. Arens beneficially owns 14,093,416 shares (10.82%). The filing is a joint Schedule 13G/A stating shared voting and dispositive power for the Manager and Mr. Arens.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 2, 2026, he exercised 5,372 restricted stock units into common stock and, in connection with vesting, surrendered shares to the company to satisfy tax obligations. The filings show 2,246 common shares disposed through issuer withholding across May 1 and May 2, 2026, and he now directly holds 25,153 shares of common stock. He also retains multiple unexercised stock option and RSU awards with exercise prices between $9.83 and $14.62 per share and expirations extending to 2036.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported updated equity holdings in the company. The filing shows a disposition of 1,042 shares of common stock on May 1, 2026 as a tax-withholding transaction, leaving her with 92,182 common shares held directly.
Alongside these shares, she holds a range of equity awards in the form of restricted stock units, performance stock units and stock options tied to NeoGenomics common stock, with various exercise prices and expiration dates, reflecting a substantial, long-term incentive position rather than open-market trading activity.
NeoGenomics, Inc. President & Chief Operating Officer Warren Stone reported routine equity compensation activity involving restricted stock units and stock options. On May 2, 2026, he exercised awards to acquire 5,969 shares of common stock, with 2,349 shares withheld by the company to cover tax obligations related to the RSU release.
Following these transactions, Stone holds 161,985 shares of common stock directly, along with a substantial remaining equity incentive position, including 253,378 stock options at an exercise price of $10.81 and 166,113 stock options at $11.21, plus significant restricted and performance stock units that vest over future years.
NeoGenomics Inc Schedule 13G shows Vanguard Capital Management beneficially owns 6,610,272 shares of Common Stock, representing 5.09% of the class.
The filing lists sole dispositive power over 6,610,272 shares and sole voting power over 954,449 shares, and is signed on 04/30/2026.
Vanguard Portfolio Management reports beneficial ownership of 7,677,794 shares of NeoGenomics Inc. under Schedule 13G, representing 5.91% of the outstanding common stock as reported. The filing shows Vanguard has 55,607 shares with sole voting power and 7,677,794 shares with sole dispositive power.
The disclosure lists the issuer CUSIP 64049M209 and identifies Vanguard affiliates included in the reporting group. Signature is by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026.
NeoGenomics, Inc. reported strong first quarter 2026 results with revenue rising 11% year over year to a record $187 million, driven by 14% growth in Clinical revenue and higher average revenue per test.
Net loss narrowed 34% to $17.1 million, while Adjusted EBITDA improved to $9.0 million from $7.1 million, and Adjusted Net Income reached $1.4 million. Gross profit rose to $80.9 million with a 43% margin, and adjusted gross margin was 46%.
The company raised its full-year 2026 revenue guidance to $797–$803 million, implying about 10% growth from 2025, and reaffirmed Adjusted EBITDA guidance of $55–$57 million. NeoGenomics also launched its RaDaR ST MRD assay, expanded its PanTracer portfolio, and ended the quarter with $146 million in cash and cash equivalents.
NeoGenomics reports that 2025 delivered 10% revenue growth and improved profitability metrics as the company deepened penetration in community oncology. Management highlights a full clinical launch of RaDaR® ST for MRD, expansion of the PanTracer therapy selection portfolio, targeted commercial hires, and a $30 billion combined addressable market for therapy selection and MRD.
Financially, revenue reached $727,332 (in thousands) in 2025 and adjusted EBITDA was $43,357 (in thousands); shares outstanding were 129,812,211 as of February 13, 2026. The company emphasizes continued R&D and commercial investment into 2026.
NeoGenomics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. Proposals include electing nine directors, approving executive pay on an advisory basis, expanding the 2023 Equity Incentive Plan, and ratifying Deloitte & Touche LLP as auditor for 2026.
The equity plan amendment would increase shares reserved for issuance by 5,000,000 shares to a total of 13,300,000 shares, supporting future stock options and RSUs. As of March 23, 2026, 1,961,604 shares remained available and 13,934,021 options and stock awards were outstanding. The proxy also highlights strong board independence, share ownership guidelines, and extensive stockholder outreach on compensation and governance.